We proudly present our highlights of 2025 in this report.
2025 was a year of strategic focus at CHDR. We completed our strategy for 2025–2030, strengthened our commitment to scientific excellence in early-phase drug development, and prepared our organisation for sustainable growth. A major milestone was the opening of our new clinical research unit in Twente and the launch of NeuroKit®, expanding global access to CHDR’s CNS methodologies.
The report offers a preview of our upcoming annual report, celebrating a year of innovation and collaboration.
Stay tuned for our full annual report!